MicroRNA-566 activates EGFR signaling and its inhibition sensitizes glioblastoma cells to nimotuzumab

Kai Liang Zhang, Xuan Zhou, Lei Han, Lu Yue Chen, Ling Chao Chen, Zhen Dong Shi, Ming Yang, Yu Ren, Jing Xuan Yang, Thomas S. Frank, Chuan Bao Zhang, Jun Xia Zhang, Pei Yu Pu, Jian Ning Zhang, Tao Jiang, Eric Wagner, Min Li, Chun Sheng Kang

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background: Epidermal growth factor receptor (EGFR) is amplified in 40% of human glioblastomas. However, most glioblastoma patients respond poorly to anti-EGFR therapy. MicroRNAs can function as either oncogenes or tumor suppressor genes, and have been shown to play an important role in cancer cell proliferation, invasion and apoptosis. Whether microRNAs can impact the therapeutic effects of EGFR inhibitors in glioblastoma is unknown.Methods: miR-566 expression levels were detected in glioma cell lines, using real-time quantitative RT-PCR (qRT-PCR). Luciferase reporter assays and Western blots were used to validate VHL as a direct target gene of miR-566. Cell proliferation, invasion, cell cycle distribution and apoptosis were also examined to confirm whether miR-566 inhibition could sensitize anti-EGFR therapy.Results: In this study, we demonstrated that miR-566 is up-regulated in human glioma cell lines and inhibition of miR-566 decreased the activity of the EGFR pathway. Lentiviral mediated inhibition of miR-566 in glioblastoma cell lines significantly inhibited cell proliferation and invasion and led to cell cycle arrest in the G0/G1 phase. In addition, we identified von Hippel-Lindau (VHL) as a novel functional target of miR-566. VHL regulates the formation of the β-catenin/hypoxia-inducible factors-1α complex under miR-566 regulation.Conclusions: miR-566 activated EGFR signaling and its inhibition sensitized glioblastoma cells to anti-EGFR therapy.

Original languageEnglish (US)
Article number63
JournalMolecular Cancer
Volume13
Issue number1
DOIs
StatePublished - Mar 20 2014
Externally publishedYes

Fingerprint

Glioblastoma
MicroRNAs
Epidermal Growth Factor Receptor
Cell Proliferation
Glioma
Cell Line
Apoptosis
Hypoxia-Inducible Factor 1
Catenins
Cell Cycle Resting Phase
G1 Phase
Therapeutic Uses
Cell Cycle Checkpoints
nimotuzumab
Tumor Suppressor Genes
Luciferases
Oncogenes
Real-Time Polymerase Chain Reaction
Cell Cycle
Therapeutics

Keywords

  • Combination therapy
  • EGFR
  • Glioblastoma
  • miR-566
  • Nimotuzumab

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Oncology

Cite this

Zhang, K. L., Zhou, X., Han, L., Chen, L. Y., Chen, L. C., Shi, Z. D., ... Kang, C. S. (2014). MicroRNA-566 activates EGFR signaling and its inhibition sensitizes glioblastoma cells to nimotuzumab. Molecular Cancer, 13(1), [63]. https://doi.org/10.1186/1476-4598-13-63

MicroRNA-566 activates EGFR signaling and its inhibition sensitizes glioblastoma cells to nimotuzumab. / Zhang, Kai Liang; Zhou, Xuan; Han, Lei; Chen, Lu Yue; Chen, Ling Chao; Shi, Zhen Dong; Yang, Ming; Ren, Yu; Yang, Jing Xuan; Frank, Thomas S.; Zhang, Chuan Bao; Zhang, Jun Xia; Pu, Pei Yu; Zhang, Jian Ning; Jiang, Tao; Wagner, Eric; Li, Min; Kang, Chun Sheng.

In: Molecular Cancer, Vol. 13, No. 1, 63, 20.03.2014.

Research output: Contribution to journalArticle

Zhang, KL, Zhou, X, Han, L, Chen, LY, Chen, LC, Shi, ZD, Yang, M, Ren, Y, Yang, JX, Frank, TS, Zhang, CB, Zhang, JX, Pu, PY, Zhang, JN, Jiang, T, Wagner, E, Li, M & Kang, CS 2014, 'MicroRNA-566 activates EGFR signaling and its inhibition sensitizes glioblastoma cells to nimotuzumab', Molecular Cancer, vol. 13, no. 1, 63. https://doi.org/10.1186/1476-4598-13-63
Zhang, Kai Liang ; Zhou, Xuan ; Han, Lei ; Chen, Lu Yue ; Chen, Ling Chao ; Shi, Zhen Dong ; Yang, Ming ; Ren, Yu ; Yang, Jing Xuan ; Frank, Thomas S. ; Zhang, Chuan Bao ; Zhang, Jun Xia ; Pu, Pei Yu ; Zhang, Jian Ning ; Jiang, Tao ; Wagner, Eric ; Li, Min ; Kang, Chun Sheng. / MicroRNA-566 activates EGFR signaling and its inhibition sensitizes glioblastoma cells to nimotuzumab. In: Molecular Cancer. 2014 ; Vol. 13, No. 1.
@article{6ff7a07d1f154596955ca035dd1bf349,
title = "MicroRNA-566 activates EGFR signaling and its inhibition sensitizes glioblastoma cells to nimotuzumab",
abstract = "Background: Epidermal growth factor receptor (EGFR) is amplified in 40{\%} of human glioblastomas. However, most glioblastoma patients respond poorly to anti-EGFR therapy. MicroRNAs can function as either oncogenes or tumor suppressor genes, and have been shown to play an important role in cancer cell proliferation, invasion and apoptosis. Whether microRNAs can impact the therapeutic effects of EGFR inhibitors in glioblastoma is unknown.Methods: miR-566 expression levels were detected in glioma cell lines, using real-time quantitative RT-PCR (qRT-PCR). Luciferase reporter assays and Western blots were used to validate VHL as a direct target gene of miR-566. Cell proliferation, invasion, cell cycle distribution and apoptosis were also examined to confirm whether miR-566 inhibition could sensitize anti-EGFR therapy.Results: In this study, we demonstrated that miR-566 is up-regulated in human glioma cell lines and inhibition of miR-566 decreased the activity of the EGFR pathway. Lentiviral mediated inhibition of miR-566 in glioblastoma cell lines significantly inhibited cell proliferation and invasion and led to cell cycle arrest in the G0/G1 phase. In addition, we identified von Hippel-Lindau (VHL) as a novel functional target of miR-566. VHL regulates the formation of the β-catenin/hypoxia-inducible factors-1α complex under miR-566 regulation.Conclusions: miR-566 activated EGFR signaling and its inhibition sensitized glioblastoma cells to anti-EGFR therapy.",
keywords = "Combination therapy, EGFR, Glioblastoma, miR-566, Nimotuzumab",
author = "Zhang, {Kai Liang} and Xuan Zhou and Lei Han and Chen, {Lu Yue} and Chen, {Ling Chao} and Shi, {Zhen Dong} and Ming Yang and Yu Ren and Yang, {Jing Xuan} and Frank, {Thomas S.} and Zhang, {Chuan Bao} and Zhang, {Jun Xia} and Pu, {Pei Yu} and Zhang, {Jian Ning} and Tao Jiang and Eric Wagner and Min Li and Kang, {Chun Sheng}",
year = "2014",
month = "3",
day = "20",
doi = "10.1186/1476-4598-13-63",
language = "English (US)",
volume = "13",
journal = "Molecular Cancer",
issn = "1476-4598",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - MicroRNA-566 activates EGFR signaling and its inhibition sensitizes glioblastoma cells to nimotuzumab

AU - Zhang, Kai Liang

AU - Zhou, Xuan

AU - Han, Lei

AU - Chen, Lu Yue

AU - Chen, Ling Chao

AU - Shi, Zhen Dong

AU - Yang, Ming

AU - Ren, Yu

AU - Yang, Jing Xuan

AU - Frank, Thomas S.

AU - Zhang, Chuan Bao

AU - Zhang, Jun Xia

AU - Pu, Pei Yu

AU - Zhang, Jian Ning

AU - Jiang, Tao

AU - Wagner, Eric

AU - Li, Min

AU - Kang, Chun Sheng

PY - 2014/3/20

Y1 - 2014/3/20

N2 - Background: Epidermal growth factor receptor (EGFR) is amplified in 40% of human glioblastomas. However, most glioblastoma patients respond poorly to anti-EGFR therapy. MicroRNAs can function as either oncogenes or tumor suppressor genes, and have been shown to play an important role in cancer cell proliferation, invasion and apoptosis. Whether microRNAs can impact the therapeutic effects of EGFR inhibitors in glioblastoma is unknown.Methods: miR-566 expression levels were detected in glioma cell lines, using real-time quantitative RT-PCR (qRT-PCR). Luciferase reporter assays and Western blots were used to validate VHL as a direct target gene of miR-566. Cell proliferation, invasion, cell cycle distribution and apoptosis were also examined to confirm whether miR-566 inhibition could sensitize anti-EGFR therapy.Results: In this study, we demonstrated that miR-566 is up-regulated in human glioma cell lines and inhibition of miR-566 decreased the activity of the EGFR pathway. Lentiviral mediated inhibition of miR-566 in glioblastoma cell lines significantly inhibited cell proliferation and invasion and led to cell cycle arrest in the G0/G1 phase. In addition, we identified von Hippel-Lindau (VHL) as a novel functional target of miR-566. VHL regulates the formation of the β-catenin/hypoxia-inducible factors-1α complex under miR-566 regulation.Conclusions: miR-566 activated EGFR signaling and its inhibition sensitized glioblastoma cells to anti-EGFR therapy.

AB - Background: Epidermal growth factor receptor (EGFR) is amplified in 40% of human glioblastomas. However, most glioblastoma patients respond poorly to anti-EGFR therapy. MicroRNAs can function as either oncogenes or tumor suppressor genes, and have been shown to play an important role in cancer cell proliferation, invasion and apoptosis. Whether microRNAs can impact the therapeutic effects of EGFR inhibitors in glioblastoma is unknown.Methods: miR-566 expression levels were detected in glioma cell lines, using real-time quantitative RT-PCR (qRT-PCR). Luciferase reporter assays and Western blots were used to validate VHL as a direct target gene of miR-566. Cell proliferation, invasion, cell cycle distribution and apoptosis were also examined to confirm whether miR-566 inhibition could sensitize anti-EGFR therapy.Results: In this study, we demonstrated that miR-566 is up-regulated in human glioma cell lines and inhibition of miR-566 decreased the activity of the EGFR pathway. Lentiviral mediated inhibition of miR-566 in glioblastoma cell lines significantly inhibited cell proliferation and invasion and led to cell cycle arrest in the G0/G1 phase. In addition, we identified von Hippel-Lindau (VHL) as a novel functional target of miR-566. VHL regulates the formation of the β-catenin/hypoxia-inducible factors-1α complex under miR-566 regulation.Conclusions: miR-566 activated EGFR signaling and its inhibition sensitized glioblastoma cells to anti-EGFR therapy.

KW - Combination therapy

KW - EGFR

KW - Glioblastoma

KW - miR-566

KW - Nimotuzumab

UR - http://www.scopus.com/inward/record.url?scp=84899582313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899582313&partnerID=8YFLogxK

U2 - 10.1186/1476-4598-13-63

DO - 10.1186/1476-4598-13-63

M3 - Article

C2 - 24650032

AN - SCOPUS:84899582313

VL - 13

JO - Molecular Cancer

JF - Molecular Cancer

SN - 1476-4598

IS - 1

M1 - 63

ER -